Remove Genetics Remove Immune Response Remove In-Vitro Remove Radiology
article thumbnail

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in.

The Pharma Data

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442.

Trials 52
article thumbnail

COVID-19 Pandemic Coverage

XTalks

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.